Document Detail

Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension.
MedLine Citation:
PMID:  12772813     Owner:  NLM     Status:  MEDLINE    
This month-long multicenter, open-label study evaluated the onset and progression of hyperemia associated with bimatoprost 0.03% once daily in 39 patients with open-angle glaucoma or ocular hypertension. Current glaucoma medication(s) was either replaced with or augmented by bimatoprost. Previous users of bimatoprost were excluded. Primary outcome measures were mean hyperemia scale scores (ciliary, conjunctival, and episcleral, graded on a seven-point scale) and incidence of hyperemia. Secondary outcome measures were fluorescein staining, patient assessment of ocular redness (take-home diary), and patient and investigator evaluations. Patients were asked how troubled they were by their ocular redness. Investigators were asked if they would continue the patient on bimatoprost despite the hyperemia. Overall, the frequency and severity of hyperemia peaked approximately 1 day after the first instillation of bimatoprost and decreased consistently throughout the study, returning to near-baseline levels by day 28. At day 1, 84.6% of patients were hardly troubled or not troubled by their ocular redness; only 15.4% were somewhat or moderately troubled. Investigators indicated that they would continue bimatoprost therapy in 92.3% of the patients. Hyperemia did not represent a significant safety concern.
Mark B Abelson; Michael Mroz; Sarah A Rosner; Monte S Dirks; Dean Hirabayashi
Related Documents :
677213 - Association of presumed ocular histoplasmosis with hla-b7.
20230203 - Diagnostic use of botulinum toxin in patients with duane syndrome.
24030183 - New insights into steroidogenesis in normo- and hyperandrogenic polycystic ovary syndro...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Advances in therapy     Volume:  20     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2003 Jan-Feb
Date Detail:
Created Date:  2003-05-29     Completed Date:  2003-06-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-13     Citation Subset:  T    
Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Topical
Aged, 80 and over
Cloprostenol / analogs & derivatives
Dose-Response Relationship, Drug
Drug Administration Schedule
Evaluation Studies as Topic
Follow-Up Studies
Glaucoma, Open-Angle / diagnosis,  drug therapy*
Hyperemia / chemically induced*,  epidemiology
Intraocular Pressure / drug effects
Lipids / adverse effects*,  therapeutic use
Middle Aged
Ocular Hypertension / diagnosis,  drug therapy
Ophthalmic Solutions
Risk Assessment
Severity of Illness Index
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Amides; 0/Lipids; 0/Ophthalmic Solutions; 0/bimatoprost; 40665-92-7/Cloprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The development of an educational workshop on complementary and alternative medicine: what every nur...
Next Document:  Sequential chemoradiotherapy versus radiotherapy in the management of locally advanced non-small-cel...